Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017

Aug 31, 2010, 11:58 ET from Reportlinker

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Women's Infertility - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0286181/Women's-Infertility---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Women's Infertility - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Women's Infertility - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global women's infertility therapeutics market. The report identifies the key trends shaping and driving the global women's infertility therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global women's infertility sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global women's infertility market was valued at $1,417m in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% to reach $1,609m by 2017. The slow market growth is attributed to the patent expiry of the branded products such as Cetrotide and Ovidrel in 2015. Some key branded products, such as Cetrotide, GONAL-f, Crinone, Ovidrel, Luveris, Pergoveris and Puregon, are going to face a severe threat from generics as they approach patent expiry between 2010 and 2015

Scope

The Scope of the report includes:

- Annualized global women's infertility therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.

- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Gonadotropin-Releasing hormone (GnRH) antagonists, AMP-activated protein kinase (AMPK) agonists, GnRH agonists, Recombinant human chorionic gonatropin, Follicle stimulating hormone, Selective Estrogen Receptor Modulators (SERMs) and aromatase inhibitor.

- Analysis of the current and future market competition in the global women's infertility therapeutics market. The key future market players covered are Ferring Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd. and PregLem SA and Merck.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the women's infertility market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

- Develop business strategies by understanding the trends shaping and driving the global women's infertility therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global women's infertility therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the global women's infertility therapeutics market landscape? Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Women's Infertility: Introduction 4

2.1 GlobalData Pipeline Report Guidance 4

3 Women's Infertility: Market Characterization 5

3.1 Women's Infertility Market Size 5

3.2 Women's Infertility Therapeutics Market Forecast and CAGR 6

3.3 Drivers and Barriers for the Women's Infertility Therapeutics Market 7

3.3.1 Drivers for the Women's Infertility therapeutics market 7

3.3.2 Barriers for the Women's Infertility therapeutics market 7

3.4 Opportunity and Unmet Need 7

3.5 Key Takeaway 8

4 Women's Infertility: Competitive Assessment 9

4.1 Overview 9

4.2 Strategic Competitor Assessment 9

4.3 Major Marketed Products for Women's Infertility 10

4.3.1 Clomid (clomiphene citrate) 10

4.3.2 Ovidrel (Choriogonadotropin Alfa) 10

4.3.3 GONAL-f (follitropin alfa) 11

4.3.4 Cetrotide (cetrorelix acetate) 12

4.4 Comparison of Major Marketed Products for Women's Infertility 14

4.5 Key Takeaway 14

5 Women's Infertility: Pipeline Assessment 15

5.1 Overview 15

5.2 Strategic Pipeline Assessment 15

5.2.1 Technology Trends Analytic Framework 15

5.3 Women's Infertility Therapeutics – Promising Drugs under Clinical Development 17

5.4 Molecule Profile for Promising Drugs under Clinical Development 17

5.4.1 ELONVA (corifollitropin alfa injection) 17

5.5 Women's Infertility Therapeutics – Clinical Pipeline by Mechanism of Action 18

5.6 Women's Infertility Therapeutics – Pipeline by Clinical Phases of Development 19

5.6.1 Women's Infertility Therapeutics – Phase III Clinical Pipeline 19

5.6.2 Women's Infertility Therapeutics – Phase II Clinical Pipeline 20

5.6.3 Women's Infertility Therapeutics – Phase I Clinical Pipeline 20

5.6.4 Women's Infertility Therapeutics – Preclinical and Discovery Clinical Pipeline 20

5.7 Key Takeaway 20

6 Women's Infertility: Implications for Future Market Competition 21

7 Women's Infertility: Future Players in the Women's Infertility Market 22

7.1 Introduction 22

7.2 Merck & Co. 22

7.2.1 Company Overview 22

7.2.2 Financial Performance 22

7.2.3 Business Description 23

7.3 Dong-A Pharmaceuticals 24

7.3.1 Company Overview 24

7.4 Ferring Pharmaceuticals 25

7.4.1 Company Overview 25

7.5 PregLem SA 26

7.5.1 Company Overview 26

8 Women's Infertility: Appendix 27

8.1 Market Definitions 27

8.2 Scope of Pipeline Research 27

8.3 Abbreviations 27

8.4 Research Methodology 28

8.4.1 Coverage 28

8.4.2 Secondary Research 29

8.4.3 Forecasting 29

8.4.4 Primary Research 31

8.4.5 Expert Panel Validation 32

8.5 Contact Us 32

8.6 Disclaimer 32

8.7 Sources 32

1.1 List of Tables

Table 1: Women's Infertility Therapeutics Market, Global, Revenue ($m), 2001–2009 5

Table 2: Women's Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2009–2017 6

Table 3: Comparison of Major Marketed Products for Women's Infertility, 2010 14

Table 4: Women's Infertility Therapeutics – Promising Drugs Under Clinical Development, 2010 17

Table 5: Women's Infertility Therapeutics – Phase III Clinical Pipeline, 2010 19

Table 6: Women's Infertility Therapeutics – Phase II Clinical Pipeline, 2010 20

Table 7: Women's Infertility Therapeutics – Phase I Clinical Pipeline, 2010 20

Table 8: Women's Infertility Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010 20

Table 9: Merck & Co. – Women's Healthcare Pipeline Products, 2010 24

Table 10: Merck & Co. – Women's Infertility Pipeline Portfolio, 2010 24

Table 11: Dong-A Pharmaceutical Co., Ltd. – Women's Health Pipeline Portfolio, 2010 25

Table 12: Dong-A Pharmaceutical Co., Ltd. – Women's Infertility Pipeline Portfolio, 2010 25

Table 13: Ferring Pharmaceuticals – Women's Health Pipeline Portfolio, 2010 26

Table 14: Ferring Pharmaceuticals – Women's Infertility Pipeline Portfolio, 2010 26

Table 15: PregLem SA – Women's Health Pipeline Portfolio, 2010 26

Table 16: PregLem SA – Women's Infertility Pipeline Portfolio, 2010 26

1.2 List of Figures

Figure 1: Women's Infertility Therapeutics Market, Global, Revenue ($m), 2001–2009 5

Figure 2: Women's Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2009–2017 6

Figure 3: Opportunity and Unmet Need in the Women's Infertility Market, 2010 8

Figure 4: Strategic Competitor Assessment of the Marketed Products for Women's Infertility, 2010 9

Figure 5: Technology Trends Analytic Framework of Women's Infertility Pipeline, 2010 16

Figure 6: Technology Trends Analytic Framework of Women's Infertility Pipeline – Description, 2010 16

Figure 7: Women's Infertility Therapeutics– Clinical Pipeline by Mechanism Of Action, 2010 18

Figure 8: Women's Infertility Therapeutics Pipeline by Phase of Clinical Development, 2010 19

Figure 9: Women's Infertility – Implications for Future Market Competition, 2010 21

Figure 10: Women's Infertility Therapeutics Market – Clinical Pipeline by Company, 2010 22

Figure 11: GlobalData Methodology 28

Figure 12: GlobalData Market Forecasting Model 31

Companies mentioned

Merck & Co.

Dong-A Pharmaceuticals

Ferring Pharmaceuticals

PregLem SA

To order this report:

Pathology Industry: Women's Infertility - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com